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Bone turnover, which is determined by osteoclast-mediated bone resorption and osteoblast-mediated 
bone formation, represents a highly energy consuming process. The metabolic requirements of 
osteoblast differentiation and mineralization, both essential for regular bone formation, however, 
remain incompletely understood. Here we identify the nuclear receptor peroxisome proliferator-
activated receptor (PPAR) δ as key regulator of osteoblast metabolism. Induction of PPARδ was 
essential for the metabolic adaption and increased rate in mitochondrial respiration necessary for the 
differentiation and mineralization of osteoblasts. Osteoblast-specific deletion of PPARδ in mice, in turn, 
resulted in an altered energy homeostasis of osteoblasts, impaired mineralization and reduced bone 
mass. These data show that PPARδ acts as key regulator of osteoblast metabolism and highlight the 
relevance of cellular metabolic rewiring during osteoblast-mediated bone formation and bone-turnover.
Bone formation and bone remodeling represent highly energy demanding processes1. Especially the unique vas-
cular architecture of long bones as well as large gradients in oxygen tension and nutrient supply impose metabolic 
challenges for bone resident cells2,3. Insights into the mechanisms that allow osteoblasts and osteoclasts the met-
abolic adaption to their specific microenvironment are therefore essential to understand both physiological and 
pathological bone turnover. Osteoblasts in long bones can sense low oxygen tension leading to a stabilization of 
hypoxia-induced factor (HIF) proteins, a process that controls both VEGF-dependent vascularization of bones 
and erythropoiesis within the bone marrow4,5. On a cellular level, HIF-1alpha-driven glycolysis in osteoblasts also 
directly contributes to bone formation6 and bone anabolic factors such as agonists of the Wnt signaling pathway 
can stimulate aerobic glycolysis in osteoblasts7. However, osteoblasts were also shown to consume and utilize 
large amounts of fatty acids8,9. In accordance, osteogenic differentiation of mesenchymal stem cells (MSCs) was 
reported to be paralleled by an increased mitochondrial respiration, where levels of ATP derived from oxidative 
phosphorylation peak in association with the accumulation of mitochondria that can directly support differen-
tiation of osteoblasts10,11.
These findings show that especially differentiating and mineralizing osteoblasts utilize both aerobic glycolysis 
and oxidative phosphorylation, indicating that these cells need to adjust their bioenergetic machinery in order to 
adapt to transient metabolic challenges such as low and high oxygen and varying nutrient supply. The exact reason 
for the usage of divergent energy pathways as well as the in vivo relevance of the observed increase in oxidative 
phosphorylation in differentiating osteoblasts remains unclear. Notably, glucose transporter 1 (Glut1)-mediated 
glucose uptake has been recognized as an important signal that initiates early osteoblast commitment by reg-
ulating the stability of Runt-related transcription factor 2 (Runx2)12. The signals that control the induction of 
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mitochondrial respiration dominating during later stages of osteoblast differentiation and mineralization, in turn, 
have remained elusive.
Results
Osteoblast differentiation is dependent on an increase in oxidative phosphorylation. To deter-
mine the metabolic requirements for regular osteoblast differentiation, we initially performed an extracellular 
flux analysis of in vitro cultured primary osteoblasts and their precursors. We compared the metabolic profiles 
of osteoblast precursors during steady state and upon initiation of osteoblast differentiation. These experiments 
confirmed a significantly increased oxygen consumption and oxidative phosphorylation of differentiating osteo-
blasts (Fig. 1A). Although the glycolytic activity slightly increased as well, this metabolic adaption resulted in an 
increase in the ratio between oxygen consumption rate (OCR, an indicator for mitochondrial respiration) and 
the extracellular acidification rate (ECAR, an indicator for glycolysis), suggestive of a robust metabolic rewiring 
of differentiating osteoblasts. In accordance, we observed a time-dependent increase in the expression of multi-
ple genes involved in the control of mitochondrial respiration, mitochondrial biogenesis and oxygen-dependent 
energy provision such as Peroxisome proliferator-activated receptor gamma coactivator 1 (PGC1)α, mitochon-
drial transcription factor A (TFAM) or dynamin-1-like protein (DRP)1 in differentiating osteoblasts (Fig. 1B). 
Pharmacologic inhibition of mitochondrial biogenesis by tigecycline13 or of oxidative phosphorylation by rote-
none, in turn, did not interfere with osteoblast viability, but dramatically diminished their differentiation and 
mineralization potential (Fig. 1C,D and Suppl. Fig. 1). These data indicated a global shift in the transcriptional 
program that controlled the cellular metabolic adaption during osteoblast differentiation and mineralization.
Figure 1. Osteoblast differentiation is dependent on an increase in oxidative phosphorylation. (A) Oxygen 
consumption rate (OCR) and the extracellular acidification rate (ECAR) including basal and maximal 
respiration rate measured with extracellular flux (XF) analyzer in freshly isolated calvarial osteoblasts cultured 
in regular growth medium (black) and differentiation medium (grey) for 24 hours (n = 9 each). (B) Real-time 
PCR analysis of mRNA expressions normalized to β-actin in calvarial osteoblasts cultured in regular growth 
media (black) and differentiation media (grey) for 6, 24 and 72 hours (n = 3). (C) Alizarine Red staining of 
calvarial osteoblasts cultured in osteoblastic differentiation media supplemented with 10 ng/ml Wnt3a and 
conditionally supplemented with vehicle (control), 30 µM tigecycline or 20 nM Rotenone at day 3, 19 and 40 
of culture (representative for n = 3). (D) Quantitative analysis of mineralized areas of alizarine red staining 
of calvarial osteoblasts supplemented with 10 ng/ml Wnt3a and conditionally supplemented with 30 µM 
Tigezycline (green) or 20 nM Rotenone (yellow) cultured in osteoblastic differentiation media for 40 days 
(n = 3). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005 using two-tailed Student’s t-test.
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The nuclear receptor PPARδ mediates metabolic rewiring of osteoblasts. PGC1α is considered 
a master regulator of mitochondrial biogenesis and was among the most highly induced genes in differenti-
ating osteoblasts. As PGC1alpha serves as co-activator and interacts with various other transcription factors, 
we next assessed expression levels of genes encoding for proteins that represent known PGC1α interaction 
partners involved in cellular metabolism and oxidative phosphorylation. This analysis identified peroxisome 
proliferator-activated receptor (PPAR)δ as one of the prominently expressed transcription factors in differentiat-
ing osteoblasts (Fig. 2A–C). PPARδ belongs to the superfamily of nuclear receptors and acts as a ligand-dependent 
transcription factor that senses fatty acids and subsequently controls fatty acid oxidation, a process that primar-
ily fuels mitochondrial respiration. We have previously identified PPARδ as important regulator of Wnt sign-
aling and osteoblast/osteoclast crosstalk14,15. Our current analysis showed that expression of PPARδ gradually 
increased during early osteogenic differentiation, whereas expression levels of its family members PPARα and 
PPARγ  remained low (Fig. 2A–C). We additionally confirmed expression of PPARδ on a protein level, which was 
induced during osteogenic differentiating of wild-type, but not in PPARδ-deficient MSCs (Fig. 2B). In accord-
ance, induction of PPARδ was paralleled by induction of several known PPARδ target genes such as carnitine pal-
mitoyltransferase (CPT)-1 or pyruvate dehydrogenase kinase (PDK)4, with expression levels likewise increasing 
during osteoblast differentiation (Fig. 2D). As expected, chromatin immunoprecipitation experiments confirmed 
direct binding of PPARδ to these known target genes also in osteoblasts (Fig. 2E). Next, we sought to determine 
whether induction of PPARδ indeed controlled the metabolic rewiring and increase in oxidative phosphoryla-
tion we had observed during osteogenic differentiation. We consequently analyzed the metabolic phenotype of 
PPARδ-deficient osteoblasts. Absence of PPARδ resulted in suppression of the expression of metabolic key genes 
such as PGC1α (Fig. 2F). This finding indicated that PPARδ controlled a transcriptional program that regulated 
mitochondrial metabolism and oxidative phosphorylation during osteoblast differentiation. The expression levels 
of metabolic genes such as glucose transporter (Glut)1 or Glut3, which are involved in glycolysis, in turn, were 
not suppressed, but even increased in PPARδ-deficient osteoblasts (Fig. 2G). The PPARδ-mediated regulation of 
genes involved in oxidative phosphorylation accordingly resulted in a reduced oxygen consumption and impaired 
oxidative phosphorylation in PPARδ-deficient osteoblasts, whereas glycolysis was increased (Fig. 2H).
Absence of PPARδ in osteoblasts alters their differentiation and mineralization. To under-
stand whether osteoblast differentiation and/or mineralization were dependent on this PPARδ-mediated met-
abolic rewiring, we studied osteoblast differentiation in the absence of PPARδ. In comparison to wild-type 
osteoblast, PPARδ-deficient cells showed a defective upregulation of osteoblast differentiation markers such as 
Runx2, osteocalcin (OCN), osterix (Osx), and alkaline phosphatase (ALP) (Fig. 3A). PPARδ-deficient MSCs 
accordingly displayed a defective mineralization upon induction of osteogenic differentiation, demonstrating 
an important intrinsic role of the PPARδ-controlled metabolic adaption during osteoblast differentiation and 
function (Fig. 3B,C). To determine the in vivo relevance of the observed phenotype, we generated mice carry-
ing an osteoblast-specific deletion of PPARδ. Analysis of these Runx2crePPARdfl/fl mice showed that these ani-
mals displayed a reduced bone mass in comparison to their wild type littermates with a significantly decreased 
bone volume/total volume, lower trabecular number and decreased bone mineral density in both tibia and spine 
(Fig. 3D–F). This low bone mass phenotype was associated with a reduced number of osteoblasts and a tendency 
towards a reduced mineral apposition and bone formation rate (Fig. 3G).
Discussion
Nuclear receptors including the members of the PPAR family control pleotropic processes throughout the body, 
including control of fatty acid and glucose metabolism in liver, adipose tissue and muscle16. Previous data have 
identified PPARδ as important regulator of bone turnover and musculoskeletal homeostasis14,17. Although these 
studies determined a contribution of this nuclear receptor during muscle and bone biology as well as during 
osteoblast/osteoclast crosstalk, its exact molecular role during bone formation remained unclear. Our cur-
rent data expand these insights on the involvement of this nuclear receptor in osteoblast biology and reveal an 
osteoblast-intrinsic role of this nuclear receptor during bone homeostasis in vivo. We show that PPARδ regulates 
the metabolic adaption and increased mitochondrial respiration, events that are required for efficient osteoblast 
differentiation and mineralization.
It remains to be determined to which extend the PPARδ-mediated control of energy homeostasis accounts for 
the reduced mineralization and bone mass observed in Runx2crePPARdfl/fl mice and whether additional effects 
exerted by this transcription factor contribute to this phenotype. Control of osteoblast-intrinsic mitochondrial 
respiration, however, seems to critically influence differentiation and mineralization of this cell type. Although 
mice that carry a Sox2-mediated complete depletion of PPARδ also showed an altered OPG/RANKL ratio and 
an increased osteoclast differentiation14, the current Runx-2-meidated osteoblast-specific deletion of this nuclear 
receptor primarily resulted in osteoblast-intrinsic effects and reduced mineralization without increasing oste-
oclast differentiation, suggesting predominant effects of PPARδ on osteoblast metabolism, differentiation and 
mineralization. The exact reason for this discrepancy is unclear, but might be due an additional PPARδ-mediated 
control of the OPG/RANKL system in cells others than osteoblasts.
PPARδ belongs to the nuclear receptor superfamily of transcription factors. Its close family member PPARγ  
acts as key factor during adipocyte differentiation. Although both PPARγ  and PPARδ sense a repertoire of lipo-
philic compounds and subsequently act as ligand-activated transcription factors, they dictate partially opposing 
cellular pathways such as fatty acid synthesis and fatty acid oxidation. Moreover, PPARγ  and PPARδ are differen-
tially expressed in distinct cell types such as adipocytes and osteoblasts. Ligand-induced activation of these differ-
ent PPAR family members accordingly exerts contrasting effects on both systemic energy and bone metabolism15. 
These findings highlight the importance of such metabolic sensors during cellular fate decision processes and 
4SCIENTIFIC REPORTS |         (2020) 10:8428  | https://doi.org/10.1038/s41598-020-65305-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 2. PPARδ-mediated metabolic rewiring of osteoblasts. (A) Quantitative real-time PCR analysis of 
PPAR isoforms (α, δ and γ) normalized to β-actin in calvarial osteoblasts cultured in differentiation media 
for 24 hours (n = 3). (B) Immunofluorescence microscopy of PPARδ wildtype and PPARδ-deficient MSCs 
cultured in differentiation medium for 7 days (β-actin, green; DAPI, blue; PPARδ, red; representative for 3 
independent experiments). (C) Quantitative real-time PCR analysis of PPARδ mRNA expression normalized 
to β-actin of osteoblasts cultured in regular growth medium (black) and differentiation media (grey) for 24 and 
72 hours (n = 3). (D) Real-time PCR analysis of mRNA expressions of CPT, PDK4 and UCP3 normalized to 
β-actin in calvarial osteoblasts cultured in regular growth media (black) and differentiation media (grey) for 
24 and 72 hours (n = 3). (E) Chromatin immunoprecipitation (ChIP) assays determining binding of PPARδ 
to the promoters of indicated genes in calvarial osteoblasts cultured in regular growth media (black) and 
differentiation media (grey) for 72 hours. (F,G) Real-time PCR analysis of mRNA expressions of (F) PGC1alpha 
and (G) Glut1 and Glut3 normalized to β-actin in PPARδ wildtype (black and grey) and PPARδ-deficient (dark 
and light blue) calvarial osteoblasts cultured in either regular growth media or differentiation media (n = 3). 
(H) OCR, ECAR, basal and maximal respiration rate measured in freshly isolated PPARδ wildtype (grey) and 
PPARδ-deficient (light blue) calvarial osteoblasts cultured in differentiation medium for 24 hours (n = 3). 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005, **** P ≤ 0.001 using two-tailed Student’s t-test.
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Figure 3. Absence of PPARδ in osteoblasts alters their differentiation and mineralization. (A) Real-time 
PCR analysis of mRNA expressions of Runx2, OCN, Osx and ALP normalized to β-actin in PPARδ wildtype 
(black and grey) and PPARδ-deficient (dark and light blue) calvarial osteoblasts cultured in either regular 
growth medium or differentiation media for 6, 24 and 72 hours (n = 3). (B) Alizarine Red staining of PPARδ 
wildtype and PPARδ-deficient MSCs cultured in osteoblastic differentiation media supplemented with 10 ng/
ml Wnt3a at day 3, 7 and 10 of culture (n = 3). (C) Quantitative analysis of mineralized areas of alizarine red 
staining of PPARδ wildtype (black) and PPARδ-deficient (blue) MSCs cultured in osteoblastic differentiation 
medium for 10 days (n = 3). (D,E) µCT images of (D) tibial and (E) vertebral bone of female wild type mice 
(PPARdfl/fl) or their female littermates carrying an osteoblast-specific deletion of PPARδ (Runx2crePPARdfl/
fl) at 12 weeks of age. (F) µCT-based analysis of structural bone parameters including bone volume per total 
volume (BV/TV), trabecular number (Trab.Numb.), trabecular separation (Trab.Sp.) and bone mineral density 
(BMD) of tibial (upper panel) and vertebral (lower panel) bone of female wild type mice (black) or their 
female littermates carrying an osteoblast-specific deletion of PPARδ (blue) at 12 weeks of age (n = 6–9). µCT 
analysis was performed using the operating system “Open VMS” by SCANCO Medical (Version 6.1). (G) 
Histomorphometric analysis of percentage of surfaces covered by osteoblast (OB.S/BS), osteoblast number 
(N.OB/B.PM), osteoclast number (N.Oc/B B.PS), mineral apposition rate (MAR) and ratio of bone formation 
to bone surface (BFR/BS) counted in the proximal tibia of wild type mice (black) or their female littermates 
carrying an osteoblast-specific deletion of PPARδ (blue) at 12 weeks of age (n = 3). *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.005 using two-tailed Student’s t-test.
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additionally provide an example where cellular metabolism and cellular differentiation of osteoblasts and other 
mesenchymal cell types are mutually interlinked.
Methods
The authors confirm that all methods were carried out in accordance with relevant guidelines and regulations.
Animals. All animal experiments were approved and carried out in accordance with relevant guidelines and 
regulations by the government of Unterfranken, Peterplatz 1, 97070 Würzburg, Germany. Mice were maintained 
at the specific pathogen-free animal care facility (FPZ) of the University of Erlangen-Nuremberg and housed in 
a room at 23 ± 2 °C, with 50 ± 10% humidity and a 12-hour light/dark cycle (lights on from 08:00 a.m. to 08:00 
p.m.). All mice were allowed free access to water and regular rodent chow. Mice with floxed PPARdelta allele exon 
(PPARfl/fl) were kindly supplied from Béatrice Desvergne, Center of Integrative Genomics, Faculty of Biology and 
Medicine, University of Lausanne, Switzerland14. Runx2-Cretg/+ mice were a gift from Jan Tuckermann, Institute 
of Comparative Molecular Endocrinology, University of Ulm, Germany.
Bone analysis. We measured the structure of tibial and vertebral bones with a SCANCO Medical µCT 40 
scanner to produce the images. Results were analyzed with SCANCO evaluation software for segmentation, 
three-dimensional morphometric analysis, density and distance parameters (SCANCO Medical AG). We per-
formed histomorphometric analysis with the OsteoMeasure Analysis System (Osteo-Metrics) to determine oste-
oclast and osteoblast parameters as previously described18.
Cell culture. Isolation of calvarial osteoblasts was previously described18. For osteoblast monocultures, 
we differentiated freshly isolated calvarial osteoblast precursors in the presence of 5 mM ß-glycerolphosphate 
(CALBIOCHEM #35675) and 100 mg/ml ascorbic acid (Sigma-Aldrich #A0278). MSCs were isolated and fully 
characterized from PPARδ wildtype and PPARδ-deficient mice bone-marrow as described previously19 confirm-
ing the mesenchymal stem cell minimal criteria20. We plated both MSC and osteoblast cell suspensions (0.5 × 106 
cells cm−2) in α-MEM (GIBCO® by life technologies #32571-028) supplemented with 10% FBS (Biowest #S1580), 
100 U/ml penicillin and 10 mg/ml streptomycin (PAN Biotech GmbH #P06-07100), at 37 °C in humidified atmos-
phere containing 5% CO2 in air. Culture media were changed every 2 days. At subconfluence, we plated cells at a 
density of 5 000 cells cm−2. MSC were used between passages 7 and 12.
Immunohistochemistry. PPARdelta immunohistochemical expression was evaluated MSC at day 7 after 
induction of osteoblast differentiation We used polyclonal anti-PPARβ from rabbit (Santa Cruz Biotechnology, 
#sc-7197) in a dilution of 1:100 in 2% BSA/PBS as previously described21. Slides were viewed under the fluores-
cence microscope ECLIPSE Ni-Series microscope, Nikon, USA.
Mineralization assay. To boost mineralization osteoblasts were cultured in a medium containing 10 ng/
ml recombinant mouse Wnt3a protein (R&D #NP_149122), ß-glycerolphosphate (CALBIOCHEM #35675) and 
ascorbic acid (Sigma-Aldrich #A0278).
Cells were stimulated with Tigecycline 30 µM. At indicated time points, cells were briefly washed with PBS 
and then fixed with 95% Ethanol for 30 minutes at room temperature. After briefly washing mineralized spots 
were dyed with 2% Alizarin Red S (Merck #A5533) in H2O (pH adjusted between 4 and 4,3) for 3 to 5 minutes. 
Then wells were washed with H2O for 5 to 8? times. Stained plates were dried and pictures were taken using the 
HP Scanjet G4050 and HP Scansoftware. Calcification areas were quantified with help of adobe photoshop CS6 
software.
Real-time PCR analysis. We isolated total RNA from cells by using TRIZOL reagent (Invitrogen). 
Concentrations were measured via NanoDrop analysis. 1 µg of isolated RNA was used for the first-strand com-
plementary DNA synthesis (Amersham Biosciences), which was then used for SYBR Green–based quantitative 
RT-PCR as described previously22. Experiments were performed in triplicate. Normalized gene expression values 
for each sample were calculated as the ratio of expression of messenger RNA (mRNA) for the gene of interest to the 
expression of mRNA for β-actin using QuantStudio™ 6 and 7 Flex Real-Time PCR System Software Base v1.x. The 
following real-time PCR primer sequences were used: ALP, 5′-CACGCGATGCAACACCACTCAGG-3′ (sense) 
and 5′-GCATGTCCCCGGGCTCAAAGA-3′ (antisense); CPT1, 5′-CCAGGCTACAGTGGGACATT-3′ (sense) 
and 5′-GAACTTGCCCATGTCCTTGT-3′ (antisense); DRP1, 5′-CTG ACG CTT GTG GAT TTA CC-3′ (sense) 
and 5′-CCC TTC CCA TCA ATA CAT CC-3′ (antisense); Glut1, 5′-TCAACACGGCCTTCACTG-3′ (sense) 
and 5′-CACGATGCTCAGATAGGACATC-3′ (antisense); Glut3, 5′-TTCTGGTCGGAATGCTCTTC-3′ (sense) 
and 5′-AATGTCCTCGAAAGTCCTGC-3′ (antisense); OCN, 5′-ACCCTGGCTGCGCTCTGTCTCT-3′ (sense) 
and 5′-GATGCGTTTGTAGGCGGTCTTCA-3′ (antisense); Osx, 5′-GGAGGCACAAAGAAGCCATACGC-3′ 
(sense) and 5′-TGCAGGAGAGAGGAGTCCATTG-3′ (antisense); PDK4, 5′-CCT TCA CAC CTT 
CAC CAC AT-3′ (sense) and 5′-AAA GAG GCG GTC AGT AAT CC-3′ (antisense); PGC1alpha, 
5′-TATGGAGTGACATAGAGTGTGCT-3′ (sense) and 5′-CCACTTCAATCCACCCAGAAAG-3′ (antisense); 
Ppara, 5′-GGACCTTCGGCAGCTGGT-3′ (sense) and 5′-TCGGACTCGGTCTTCTTGATG-3′ (antisense); 
Ppard, 5′-CTGAAGGGAAGGGGGTAGAG-3′ (sense) and 5′-CAGTCTGGATGCTGCTACA-3′ (antisense); 
Pparg, 5′-CATTCTGGCCCACCAACTTC-3′ (sense) and 5′-TCAAAGGAATGCGAGTGGTCTT-3′ (antisense); 
Runx2, 5′-GACGAGGCAAGAGTTTCACC-3′ (sense) and 5′-GGACCGTCCACTGTCACTTT-3′ (antisense); 
TFAM, 5′-GATGGCGCTGTTCCGG-3′ (sense) and 5′-TGGATAGCTACCCATGCTGGA-3′ (antisense) and 
UCP3, 5′-CCTACGACATCATCAAGGAGAAGTT-3′ (sense) and 5′-TCCAAAGGCAGAGACAAAGTGA-3′ 
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(antisense). Normalized gene expression values for each sample were calculated as the ratio of expression of 
mRNA of the gene of interest to the expression of mRNA for β-actin.
Metabolic analysis. The cells’ bioenergetics were assessed using an XFe96 Extracellular Flux Analyzer 
(Seahorse Bioscience, North Billerica, MA) as well as corresponding kits (Agilent, Santa Clara, California, USA). 
Cells were seeded in an optimized concentration of 15 000 cells per well. One hour before performance of sea-
horse experiment, cells were incubated at 37 °C in a CO2-free atmosphere. XF Mitochondrial Stress Test Kits 
(Agilent, #103015) and XF Glycolysis Stress Test Kits (Agilent, #103020) were utilized according to the user guide 
(Seahorse Bioscience) and as described before23. For the Mitochondrial Stress Test, basal oxygen consumption 
rate (OCR) (an indicator for mitochondrial respiration) and extracellular acidification rate (ECAR) (an indicator 
for lactic acid production or glycolysis) were analyzed. Next, OCR and ECAR responses toward the application 
of oligomycin (1 µM), FCCP (2.5 µM), and the combination of antimycin (3 µM) and rotenone (3 µM) were eval-
uated. For Glycolysis Stress Test, OCR and ECAR were detected. Then, OCR and ECAR responses toward the 
application of Glucose (100 mM), Oligomycin (100 µM) and 2-DG (500 mM) were evaluated.
Chromatin immunoprecipitation (ChIP) assays. To verify the binding of PPARd on selected promoters, 
ChIP assays were performed according to manufacturer instructions using the ChIP-IT® Express Chromatin 
Immunoprecipitation Kit (#53008, Active Motif, CA, USA). 25 µg of sonicated chromatin extract were incubated 
with 3.4 µg specific antibodies against PPARdelta (#ab178866, Abcam, Cambridge, MA, USA) or normal rabbit 
IgG antibodies (#sc-2027, Santa Cruz Biotechnology, CA, USA). After purification of DNA using Chromatin IP 
DNA Purification Kit (Active Motif, #58002) qPCR reactions were carried out on specific genomic regions using 
SYBR Green (Bio-Rad, USA). The resulting signals were normalized for primer efficiency by carrying out qPCR 
for each primer pair using the genomic input DNA. For positive control ChIP H3K36me3 antibody was used.
The  fol lowing  pr imers  were  us ed  in  thes e  ChIP assays :  PPRE on UCP3 promoter 
5 ′-TGTGTTGCAGACAGAAGATGG-3′  (sense) and 5 ′-ACCCCTCGTTTTACCAAAAGCAG-3′ 
( ant i s e ns e ) ;  P P R E  on  C T P 1  prom ot e r  5 ′ - TG C TAG AG ATC AG TC G G TG AG - 3 ′  ( s e ns e ) 
and 5 ′ -CT TGAACTCAGAAATCCGCCTG-3 ′  (ant is ens e)  and PPRE on PDK4 promoter 
5′-GTCCACTAAACAGCAGAGCAC-3′ (sense) and 5′-GAAAGTCATAGATGACGGTGG-3′ (antisense).
Statistical analyses. All data are presented as mean ± SEM. Tests for statistical significance were performed 
with Student’s t test using GraphPad Prism Version 5 (GraphPad Prism Software Inc. La Jolla, California, USA). 
P < 0.05 was considered as significant.
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